方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 特应性皮炎评分指数（SCORAD）× | Skindex-29（皮肤病生活质量指标）× | |
|---|---|---|
| 领域 | 皮肤病学 | 皮肤病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1993 | 1997 |
| 提出者≠ | European Task Force on Atopic Dermatitis (ETFAD) | Chren MM, Lasek RJ |
| 类型≠ | Clinician-rated | Self-report |
| 开创性文献≠ | Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| 别名≠ | SCORAD Index | Skindex, Skindex-QoL |
| 相关≠ | 3 | 1 |
| 摘要≠ | The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGate数据集 ↗ |
|
|